ACROSS2 Study by Prof. Wang Jie’s Team Published in CA: Pioneering a Precision Treatment Paradigm for EGFR-Mutant NSCLC with Concomitant Mutations Epidermal growth factor receptor (EGFR) mutations are primary lung cancer drivergene, standardly managed with third-generation tyrosine kinase inhibitors (EGFR-TKIs). However, patients withtumor suppressor gene (TSG) co-mutations, such as TP53, showed shorter progression-free survival (PFS) and faster resistance on monotherapy. On March 12, 2026, ACROSS2 study initiated by Professor Wang Jie's team from the National Cancer Center, Chinese Academy of Medical Sciences—was published in CA: A Cancer Journal for Clinicians. As the world's first prospective phase III study targeting EGFR-mutant NSCLC with TSG co-mutations, it demonstrated that first-line aumolertinib plus chemotherapy significantly prolongs PFS, particularly in patients with TP53 co-mutations. These findings furnish high-level evidence and a novel Chinese paradigm fo...

Recently, the team of Professor Haiyue Jiang at the Plastic Surgery Hospital of Chinese Academy of Medical Sciences, in collaboration with the team of Professor Y. Shrike Zhang at Harvard Medical School, published a research article online in Nature Biomedical Engineering, entitled "4D-printed adaptive hydrogel tissue expanders for ear and breast reconstruction." Based on a polyelectrolyte poly(acrylic acid) photocurable hydrogel system, with systematic optimization of formulation and processing combined with digital light processing (DLP) 4D printing technology, the study successfully developed a novel tissue expander (AEH-TEs) capable of environment-adaptive expansion, excellent mechanical performance, and highly personalized geometric structures, providing a complete paradigm reference for the design, fabrication, and clinical translation of next-generation surface organ reconstruction devices. Soft tissue expansion is one of the most important techniques in plastic surgery...

Professor Jianxiang Wang and Assistant ProfessorYingxi Xu from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, together with Professor Ping-Chih Ho from the Ludwig Institute for Cancer Research, University of Lausanne, Switzerland, have published a study entitled “Proteasome-guided haem signaling axis contributes to T cell exhaustion” online in Nature. Terminally exhausted T cells are a major challenge limiting the long-term effectiveness of T cell immunotherapies. These cells exhibit reduced effector functions, impaired proliferation, and persistent expression of inhibitory receptors. Although mitochondrial dysfunction has been linked to T cell exhaustion, the underlying mechanisms remain unclear. The research team found that T cells containing depolarized mitochondria showed increased proteasome activity. Proteomic analyses revealed enhanced degradation of ubiquitinated mitochondrial proteins, including haem-containing protein...

It is the world’s first ISO/IEC international standard in the field of brain-computer interfaces (BCI). The standard establishes a unified BCI terminology framework and promotes international consensus, providing an important foundation for standardizing technological research, building industry-wide consensus, and accelerating the development of new quality productive forces in the BCI sector. It is expected to strongly advance the coordinated development of BCI technologies and industries worldwide. The standard was led by Jiangbo Pu, an expert from the Institute of Biomedical Engineering, Chinese Academy of Medical Sciences, who served as the Project Leader. China formally submitted the standard proposal in March 2021, and the project was approved by vote in September of the same year. During its development, the project received strong support from leading Chinese research and standardization institutions in the BCI field, including the China Electronics Standardization In...

Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by accelerated platelet destruction and impaired platelet production [1]. Although multiple therapies are available, some patients experience relapse, limited treatment durability, or treatment-related infections. The team previously showed that CD38-targeted therapy can induce rapid platelet recovery in refractory ITP, suggesting a mechanism beyond depletion of antibody-producing cells [2–4]. Given the emerging role of immunometabolism in shaping immune-cell function, the researchers investigated whether the CD38–NAD⁺ axis regulates macrophage-mediated platelet clearance and whether restoring NAD⁺ could provide a non-cell-depleting therapeutic strategy for ITP. On April 29, 2026, the team led by Lei Zhang, Renchi Yang, and Jun Wei from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, reported their findings online in Nature M...

On June 16, 2026, the research team led by Professor Qianben Wang at the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, in collaboration with the teams of Professor Wei Li at the University of California, Irvine, and Professor Yizhou Dong at the Icahn School of Medicine at Mount Sinai, published a research article entitled “Programmable mRNA 3′UTReEngineeringrRestores MHC-I andoOvercomesiImmuneeEvasion inpProstatecCancer” in Nature Biomedical Engineering. The study uncovers a previously underappreciated mechanism by which tumor cells evade immune recognition through aberrant shortening of mRNA 3′ untranslated regions (3′UTRs) and develops a programmable mRNA 3′UTR engineering strategy, providing a new RNA-targeting approach to enhanceresponses to immunotherapyimmunotherapeutic responses in prostate cancer. Prostate cancer is generally considered an immunologically “cold” tumor and responds poorly to immune checkpoint therapy. One important reason is ...